Then often there's a small amount of recovery -- a line or two of the eye chart -- and maybe a little ... about possible links between GLP-1 receptor agonists and NAION. "It is estimated that ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, but growth may accelerate after 2026. Read more here.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis (US) service reveal ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.